TP53 and cancer: The direct action on mitochondria may be an advantage to kill cancer cells resistant to apoptosis (p53 null/mutated cells, topoisomerase 1 mutated cells, Bcl-2 overexpressing cells), providing that a selectivity for cancer cells mitochondria vs. normal cells can be delineated.